ReviewNature reviews. Urology2025
Circulating tumour DNA and circulating tumour cells in bladder cancer - from discovery to clinical implementation.
Review in Nature reviews. Urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta-analysis.BJU international · 2026Pooled it
- Assessing clinical complete response after neoadjuvant systemic therapy in muscle-invasive bladder cancer: a systematic review.World journal of urology · 2025Pooled it
- Diagnosis, evaluation, and management of patients with non-muscle invasive bladder cancer.Future science OA · 2026Review
- ctDNA in muscle-invasive bladder cancer - clinically actionable, not yet standardized.Nature reviews. Urology · 2026Article
- Prevalence of PD-L1-High Tumor Expression and Association with First-Line Treatment Outcomes in Patients with Metastatic Urothelial Carcinoma: Results from a Prospective Observational Cohort Study.Targeted oncology · 2026Article
- Circulating Tumor DNA in Bladder Cancer: Current Clinical Evidence and Emerging Multi-Omics Perspectives-A Narrative Review.Cancers · 2026Review
- ctDNA-guided treatment decisions in muscle-invasive bladder cancer.Nature reviews. Urology · 2026Article
- Circulating Tumor DNA Analysis in Adrenocortical Carcinoma: A Retrospective Cohort Study.Endocrine pathology · 2026Article
- Aligning bladder cancer research with patient needs: an update on research priorities.BJU international · 2026Article
- Article
- Nanotechnology-enabled precision strategies for bladder cancer: from in vitro diagnostics to in vivo therapy.Journal of nanobiotechnology · 2026Review
- PD-L1+ CTCs Are Associated with Adverse Pathological Features and Unfavorable Prognosis in Bladder Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Liquid biopsy in the clinical management of tumor of urinary system: current status and future developments.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- ctDNA Dynamics and Recurrence Patterns after Organ-Sparing Trimodality Therapy for Bladder Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Urinary Tumor DNA to Identify Candidates for Repeat Transurethral Resection in Non-Muscle-Invasive Bladder Cancer.Cancer science · 2026Article
- RAD54B as a biomarker for prognosis and immunotherapy response in bladder cancer.Discover oncology · 2026Article
- From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer.Frontiers in immunology · 2026Review
- Post-IMvigor011 Era: CtDNA-Guided Postoperative Adjuvant Treatment Stratification in Muscle-Invasive Bladder Cancer.Cancer management and research · 2026Review
- Bladder Cancer Biomarkers: Recent Advances in Early Detection, Treatment Prediction, and Prognosis.Oncology research · 2026Review
- Recent advances in immunotherapy for bladder cancer: mechanisms, clinical applications, and future perspectives.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquid biopsies, indicating the sampling of body fluids rather than solid-tissue biopsies, have the potential to revolutionize cancer care through personalized, noninvasive disease detection and monitoring. Circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs) are promising blood-based biomarkers in bladder cancer. Results from several studies have shown the clinical potential of ctDNA and CTCs in bladder cancer for prognostication, treatment-response monitoring, and early detection of minimal residual disease and disease recurrence. Following successful clinical trial evaluation, assessment of ctDNA and CTCs holds the potential to transform the therapeutic pathway for patients with bladder cancer - potentially in combination with the analysis of urinary tumour DNA - through tailored treatment guidance and optimized disease surveillance.
Indexed as
Identifiers
40234713What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.